Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -231.74K | -2.60M | -949.17K | -623.26K | -266.35K | -20.03K |
EBITDA | -181.48M | -158.23M | -102.46M | -52.28M | -37.62M | -15.75M |
Net Income | -143.32M | -122.53M | -89.62M | -51.32M | -38.05M | -15.88M |
Balance Sheet | ||||||
Total Assets | 866.55M | 903.33M | 482.02M | 97.84M | 111.16K | 38.70K |
Cash, Cash Equivalents and Short-Term Investments | 836.88M | 883.52M | 467.32M | 90.84M | 107.31M | 37.45M |
Total Debt | 7.59M | 3.86M | 5.45M | 260.00K | 621.00K | 280.00K |
Total Liabilities | 41.91M | 38.49M | 29.05M | 212.99M | 175.89K | 61.17K |
Stockholders Equity | 824.64M | 864.84M | 452.97M | 84.83M | -64.73K | 35.53M |
Cash Flow | ||||||
Free Cash Flow | -136.23M | -117.93M | -81.66M | -46.27M | -33.37K | -14.30K |
Operating Cash Flow | -134.78M | -116.64M | -79.49M | -46.12M | -32.16K | -14.28K |
Investing Cash Flow | -326.29M | -358.91M | -268.34M | -62.11M | 17.86K | -21.18M |
Financing Cash Flow | 514.68M | 515.26M | 451.53M | 29.01M | 103.25K | 25.84M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $1.51B | ― | -171.41% | ― | -14.98% | -51.76% | |
51 Neutral | $7.77B | -0.12 | -39.78% | 2.21% | 22.68% | -1.42% | |
43 Neutral | $752.26M | ― | -50.67% | ― | 41.86% | 10.48% | |
43 Neutral | $1.74B | ― | -61.32% | ― | ― | -7.71% | |
42 Neutral | $1.33B | ― | -86.86% | ― | ― | -82.75% | |
36 Underperform | $1.17B | ― | -25.26% | ― | ― | -3.53% | |
31 Underperform | $1.08B | ― | -21.19% | ― | ― | -39.64% |
Structure Therapeutics Inc. has announced the selection of ACCG-2671, an oral small molecule amylin receptor agonist, as its lead candidate for obesity treatment. Preclinical studies show ACCG-2671’s effectiveness in weight loss with a favorable safety profile, supporting once-daily dosing. The company plans to initiate Phase 1 clinical trials by the end of 2025. This advancement positions Structure Therapeutics as a leader in developing amylin-based treatments that could significantly impact the treatment landscape for obesity and related conditions.